| Trial ID: | L5220 |
| Source ID: | NCT00212290
|
| Associated Drug: |
Pioglitazone
|
| Title: |
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Insulin Resistance|Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: pioglitazone|DRUG: nateglinide|DRUG: placebo
|
| Outcome Measures: |
Primary: Verbal memory (main study)|Selective attention (main study)|Plasma beta-amyloid levels (main study)|Cerebral glucose metabolism (sub-study)|Inflammatory markers in spinal fluid (sub-study)|Beta-amyloid in spinal fluid (sub-study) | Secondary: Psychomotor speed|Verbal fluency|Blood levels of insulin, insulin degrading enzyme, cortisol and inflammatory markers
|
| Sponsor/Collaborators: |
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
140
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2002-11
|
| Completion Date: |
2006-12
|
| Results First Posted: |
|
| Last Update Posted: |
2010-02-15
|
| Locations: |
VA Puget Sound Health Care System (Seattle Campus), Seattle, Washington, 98108, United States|VA Puget Sound Health Care System (American Lake Campus), Tacoma, Washington, 98493, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00212290
|
